Infinity Pharmaceuticals, Grove leads healthcare gainers; Dyadic, EyeGate Pharmaceuticals among major losers

Stock Information for null

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About null

Dyadic Reports 2024 Year-End Financial Results and Business Updates
Dyadic Announces Funding Award from CEPI to Use C1 to Accelerate Development of Protein-Based Vaccines
Dyadic to Report 2024 Full Year Financial Results and Host Conference call on Wednesday, March 26, 2025
Dyadic to Attend Multiple Industry Events in March
Dyadic Provides Business Update; Dyadic to Attend the 43rd Annual J.P. Morgan Healthcare Conference
Dyadic Receives $3 Million Grant to Develop Cost-Effective Monoclonal Antibodies for RSV and Malaria Using C1 Platform Technology
Dyadic Announces Third Quarter 2024 Financial Results and Strategic Progress Across Key Markets
Dyadic to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.